Stifel, Cytokinetics
Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...
Stifel analysts kept a Buy rating on Revolve Group (NYSE:RVLV) shares, maintaining a $41.00 price target. The firm is ...
Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market ...
Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...
Stifel analysts maintained a Hold rating on Parker-Hannifin shares (NYSE:PH) with a steady price target of $691. The decision ...
Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.
Stifel analyst Drew Crum raised the firm’s price target on Take-Two (TTWO) to $223 from $220 and keeps a Buy rating on the shares. The firm ...
Wall Street analysts are buzzing with optimism as we step into 2025. There are plenty of reasons for a positive view to ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...
Stifel initiated coverage of FanDuel parent company Flutter Thursday with a $320 target price and a buy rating.
Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback